Hans Christian Reinhardt

Status: Professor for Clinical and Molecular Oncology
Address:
Clinic I of Internal Medicine
University Hospital Cologne
Weyertal 115B
50937 Köln
Phone: +49 221/478 96701
E-Mail: christian.reinhardt@uk-koeln.de
Nationality: German

 

Education

05.01.2012 Professor for Clinical and Molecular Oncology, University Hospital Cologne
05.01.2010 Certified Clinical Research Physician
Since 01.11.09 Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Medical Clinic I of the University Hospital Cologne
06.11.2008 Habilitation for Molecular Medicine at the Medical Faculty of the University of Cologne
01.12.04-10.10.09 Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD
01.01.-30.11.2004 Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.
01.06.-31.12.2003 Postdoctoral Research Fellow University of Freiburg, Germany, Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

 

Professional and research experience

15.09.2015 Attending physician (Oberarzt), Medical Clinic I, University Hospital cologne
28.05.2015 Board exam (General internal medicine, hematology and medical oncology)
31.01.2015 Member of the Executive Board, center for Molecular medicine Cologne
05.01. 2010 Certified Clinical Research Physician
Since 01.11.09

Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Medical Clinic I of the University Hospital Cologne

06.11.2008 Habilitation for Molecular Medicine, Medical Faculty, University of Cologne
01.12.04-10.10.09 Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD
01.01.-30.11.2004

Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.

01.06.-31.12.2003

Postdoctoral Research Fellow University of Freiburg, Germany, Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

 

Awards

2012 GlaxoSmithKline Medical Research Award
2011 - Vincenz Czerny Award of the German Society for Hematology and Oncology
- W2 Lichtenberg Professorship of the Volkswagen Stiftung
- CESAR Research Award of the Central European Society for Anticancer Drug Research
- Johann-Georg-Zimmermann Award for Cancer Research
2010 Young Leaders in Science Award of the Schering Stiftung
2009 - Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft
- Startup grant from the Ministerium für Wissenschaft, Forschung NRW
- NIH/NCI K99/R00 PI award (relinquished due to return to Germany)
- Travel grant of the Deutsche Krebshilfe
2007

MIT-Koch Award

2005

Research fellowship of the Deutsche Forschungsgemeinschaft

2004 Young investigator award of the Deutsche Nierenstiftung

 

Memberships

  1. Deutsche Gesellschaft für Innere Medizin
  2. Deutsche Gesellschaft für Hämatologie und Onkologie
  3. Deutscher Hochschulverband
  4. American Association for Cancer Research
  5. Central European Society for Anticancer Drug Research

 

List of the five most important publications

 

  1. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretińá L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2; 1; 146-159

  2. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, Published Online First, 2014 Feb 20.

  3. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK,   Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78. doi: 10.1126/scitranslmed.3005814.

  4. Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89.

  5. Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54.*equal contribution

 

Patents Accepted

  1. Inventors: Michael B. Yaffe, Isaac A. Manke, Daniel Lim, Hans Christian Reinhardt USPTO Application #: 20090010927 Title: MAPKAP KINASE-2 AS A SPECIFIC TARGET FOR BLOCKING PROLIFERATION OF P53-DEFECTIVE CELLS

 

Submitted

  1. Inventors: Hai Jiang, Hans Christian Reinhardt, Michael B. Yaffe, Michael T. Hemann USPTO Application #: Pending, application is being processed by the technology licensing office. Title: INHIBITION OF DNA-PKCS SENSITIZES ATM-DEFICIENT TUMORS TO GENOTOXIC CHEMOTHERAPY
  1. Inventors: Hans Christian Reinhardt, Hai Jiang, Michael B. Yaffe, Michael T. Hemann USPTO Application #: Pending, application is being processed by the technology licensing office. Title: USE OF ATM, CHK2 AND P53 STATUS TO PREDICT CHEMOTHERAPEUTIC OUTCOME
  1. Inventors: Hans Christian Reinhardt, Michael B. Yaffe, Isaac A. Manke, Daniel Lim USPTO Application #: Pending, application is being processed by the technology licensing office. Title: METHODS FOR DIAGNOSING AND TREATING CANCER File reference: 01997/570W02